

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of Huakang Biomedical Holdings Company Limited.

ANSELME LIMITED
(Incorporated in the British Virgin Islands with limited liability)


HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
華康生物醫學控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 8622)

JOINT ANNOUNCEMENT
(1) CLOSE OF MANDATORY UNCONDITIONAL CASH OFFERS BY



**FOR AND ON BEHALF OF ANSELME LIMITED
TO ACQUIRE ALL THE ISSUED SHARES AND
TO CANCEL ALL OUTSTANDING SHARE OPTIONS OF
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
(OTHER THAN THOSE ALREADY OWNED OR
AGREED TO BE ACQUIRED BY ANSELME LIMITED AND
PARTIES ACTING IN CONCERT WITH IT);
(2) RESULTS OF THE OFFERS;
(3) SETTLEMENT OF THE OFFERS;
(4) SHAREHOLDING STRUCTURE;
(5) PUBLIC FLOAT; AND
(6) APPOINTMENT OF CO-CHAIRMAN OF THE BOARD**

Joint Financial Advisers to the Offeror



Independent Financial Adviser to the Independent Board Committee



Reference is made to the joint announcements dated 9 October 2025 and the composite offer and response document dated 20 November 2025 (the “**Composite Document**”) jointly issued by Anselme Limited (the “**Offeror**”) and Huakang Biomedical Holdings Company Limited (the “**Company**”) in relation to, among other things, the mandatory unconditional cash offers by Kingston Securities Limited for and on behalf of the Offeror to acquire all the issued shares of the Company (other than those already owned or agreed to be acquired by the Offeror and parties acting in concert with it) and to cancel all the outstanding Share Options (the “**Offers**”). Unless otherwise defined, capitalised terms used in this joint announcement shall have the same meanings as those defined in the Composite Document.

CLOSE OF THE OFFERS

The Offeror and the Company jointly announce that the Offers was closed at 4:00 p.m. on Thursday, 11 December 2025 and was not revised or extended by the Offeror.

RESULTS OF THE OFFERS

As at 4:00 p.m. on Thursday, 11 December 2025, being the latest time and date for acceptance of the Offers as set out in the Composite Document, the Offeror had received (i) valid acceptances in respect of a total of 96,000 Offer Shares under the Share Offer, representing approximately 0.02% of the entire issued share capital of the Company as at the date of this joint announcement; and (ii) no acceptances under the Option Offer (with the exercise price of HK\$0.125 per Share).

SETTLEMENT OF THE OFFERS

Remittances in respect of the cash consideration (after deducting the seller’s ad valorem stamp duty) payable in respect of the Offer Shares tendered under the Share Offer have been despatched, or will be despatched to the accepting Offer Shareholders by ordinary post at their own risk as soon as possible, but in any event no later than seven (7) Business Days following the date of receipt by the Registrar (in respect of the Share Offer) of the duly completed Forms of Acceptance and all requisite documents to render the acceptance under the Offers complete and valid in accordance with the Takeovers Code.

The latest date for posting of the remittances in respect of valid acceptances received under the Offers is Monday, 22 December 2025.

SHAREHOLDING STRUCTURE OF THE COMPANY

Immediately after Completion but prior to the making of the Offers, the Offeror, Dr. Zhou and parties acting in concert with any one of them were in aggregate interested in a total of 259,424,000 Shares, representing approximately 51.84% of the then total issued share capital of the Company.

Immediately after the close of the Offers, taking into account the valid acceptances in respect of a total of 96,000 Offer Shares under the Share Offer, the Offeror, Dr. Zhou and parties acting in concert with any one of them were in aggregate interested in a total of 259,520,000 Shares, representing approximately 50.35% of the total issued share capital of the Company as at the date of this joint announcement.

Save for and except the aforesaid, none of the Offeror, Dr. Zhou and parties acting in concert with any one of them had (i) held, controlled or directed any Shares or rights over the Shares immediately before the commencement of the Offer Period; (ii) acquired or agreed to acquire any Shares or other securities of the Company or rights over the Shares during the Offer Period; or (iii) borrowed or lent any Shares or relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company during the Offer Period.

Set out below is the shareholding structures of the Company (i) immediately after Completion and prior to the making of the Offers; and (ii) immediately after the close of the Offers and as at the date of this joint announcement:

	Immediately before Completion		Immediately after Completion and prior to the making of the Offers		Immediately after the close of the Offers and as at the date of this joint announcement	
	Number of Shares	Approximate % of issued Shares	Number of Shares	Approximate % of issued Shares	Number of Shares	Approximate % of issued Shares
Shareholders						
Vendor	138,672,000	27.71	–	–	–	–
Sub-total	138,672,000	27.71	–	–	–	–
Offeror, Dr. Zhou and parties acting in concert with any one of them ^(Note)						
Offeror	120,752,000	24.13	259,424,000	51.84	259,520,000	50.35
Sub-total	120,752,000	24.13	259,424,000	51.84	259,520,000	50.35
Directors						
Zhang Chunguang	–	–	–	–	4,000,000	0.78
Poon Lai Yin Michael	4,000,000	0.8	4,000,000	0.8	4,000,000	0.78
Sub-total	4,000,000	0.8	4,000,000	0.8	8,000,000	1.56
Other employees and Optionholders						
Public Shareholders	237,048,000	47.36	237,048,000	47.36	236,952,000	45.96
Sub-total	237,048,000	47.36	237,048,000	47.36	247,952,000	48.09
Total	500,472,000	100.00	500,472,000	100.00	515,472,000	100.00

Note: The Offeror is beneficially wholly-owned by Dr. Zhou.

PUBLIC FLOAT OF THE COMPANY

Immediately after the close of the Offers and as at the date of this joint announcement, assuming that the transfer to the Offeror of those Offer Shares acquired by the Offeror under the Share Offer has been completed in full, a total of 247,952,000 Shares, representing approximately 48.09% of the entire issued share capital of the Company, are held by the public (as defined in the GEM Listing Rules). Accordingly, as at the date of this joint announcement, the Company continues to satisfy the minimum public float requirement as set out under Rule 11.23(7) of the GEM Listing Rules.

APPOINTMENT OF CO-CHAIRMAN OF THE BOARD

The Board further announces that, with effect immediately following the close of the Offers on 11 December 2025, Dr. Zhou, an executive Director, has been appointed as a co-chairman of the Board. Dr. Zhou and Ms. Zhang Yujing will provide leadership to the Board jointly as co-chairmen. The co-chairman arrangement will allow Dr. Zhou to share some of the responsibilities of Ms. Zhang, particularly those relating to the investment and business development of the Group.

The Board would like to take this opportunity to extend its warmest welcome to Dr. Zhou for taking the co-chairmanship of the Board.

By order of the Board
Anselme Limited
Zhou Xunyong
Sole Director

By order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Yujing
Co-Chairman and Executive Director

Hong Kong, 11 December 2025

As at the date of this joint announcement, Dr. Zhou Xunyong is the sole director of the Offeror. As the sole director of the Offeror, Dr. Zhou Xunyong accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Vendor and the Group) and confirm, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than that expressed by the Directors in their capacity as such) been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statements in this joint announcement misleading.

As at the date of this announcement, the Executive Directors are Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang, and Mr. Poon Lai Yin Michael; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than those relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the sole director of the Offeror in his capacity as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statements in this joint announcement misleading.

This joint announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.